Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N9F7
UPID:
GDPD1_HUMAN
Alternative names:
Glycerophosphodiester phosphodiesterase 4; Glycerophosphodiester phosphodiesterase domain-containing protein 1
Alternative UPACC:
Q8N9F7; A8W735; Q56VR1; Q8N4E3
Background:
Lysophospholipase D GDPD1, also known as Glycerophosphodiester phosphodiesterase 4, plays a crucial role in lipid metabolism by hydrolyzing lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and corresponding amines. It shows a preference for substrates like lyso-PAF, lyso-PE, and lyso-PC, and is involved in bioactive N-acylethanolamine biosynthesis. This enzyme's specificity towards certain phospholipids underlines its importance in cellular lipid remodeling and signaling.
Therapeutic significance:
Understanding the role of Lysophospholipase D GDPD1 could open doors to potential therapeutic strategies.